Ann: Human Cancer Trial - First Patient Initiates Treatment, page-9

First 9 Last

Share
Profile

Follow
samwiise

3,994 Posts.

08/08/14

10:29

Post #: 13788672
Share

Originally posted by fever2tell ↑

From Biotech Daily - Thursday August 7, 2014

PHARMAUST
Pharmaust says it has begun treatment of its first of up to 15 patients in its open-label, phase I/II dose escalation trial of PPL-1 for cancer at the Royal Adelaide Hospital.
Pharmaust said that the patient had colorectal cancer with lung and liver metastases. The company said the trial was led by Prof Michael Brown and managed by IDT’s CMax contract research organization based at the Royal Adelaide Hospital with analytical services by the Adelaide-based CPR Pharma Services.
Pharmaust said that each patient would receive PPL-1 daily for 28 days and be given the option to continue on the drug passed the initial treatment period.
Pharmaust said that PPL-1 was an approved drug launched years by an animal health corporation for the treatment of parasitic diseases in animals.
The company said that its wholly-owned subsidiary, Pitney Pharmaceuticals owned patents on the use of PPL-1 in cancer and malignant disease. Pharmaust said that University of New South Wales commercialization arm New South Innovations, it had received royalty-free assignments of the intellectual property relating to the use of PPL-1 in cancer from the University of New South Wales.
The company said that research into the mechanism of action of PPL-1 with Sydney’s St George Hospital indicated that cancer inhibitory pathways were involved in the action of the molecule.
Pharmaust executive chairman Dr Roger Aston said that “as a first-in-man study, the drug will be potentially administered to patients suffering from diverse cancers”.
“Recruitment will include selection of patients suffering from lung, pancreas, oesophageal, gastric, colorectal, ovarian, breast, prostate, liver, sarcoma, lymphoma and melanoma,” Dr Aston said.
Pharmaust was up 0.1 cents or 10 percent to 1.1 cents with 4.8 million shares traded.

Expand

1.1c this am chomp chomp

hopefully it keeps going up

Obviously people will get the munchies for PAAO the more PAA runs...

PAA Price at posting: 1.1¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

What's causing the cost-of-living crisis, and how to navigate it

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t